Identification, Synthesis, and In Vitro Activities of Antimicrobial Peptide from African Catfish against the Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli

Author:

Okella Hedmon1,Odongo Steven2ORCID,Vertommen Didier3ORCID,Okello Emmanuel14ORCID

Affiliation:

1. Veterinary Medicine Teaching and Research Center, School of Veterinary Medicine, University of California, Davis, CA 93274, USA

2. Department of Biotechnical and Diagnostic Sciences, College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala P.O. Box 7062, Uganda

3. de Duve Institute and MASSPROT Platform, UCLouvain, 1200 Brussels, Belgium

4. Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, CA 95616, USA

Abstract

The global surge in multi-drug resistant bacteria, including extended-spectrum β-lactamase (ESBL)-producing Escherichia coli has led to a growing need for new antibacterial compounds. Despite being promising, the potential of fish-derived antimicrobial peptides (AMPs) in combating ESBL-producing E. coli is largely unexplored. In this study, native African catfish antimicrobial peptides (NACAPs) were extracted from the skin mucus of farmed African catfish, Clarias gariepinus, using a combination of 10% acetic acid solvent hydrolysis, 5 kDa ultrafiltration, and C18 hydrophobic interaction chromatography. Peptides were then sequenced using Orbitrap Fusion Lumos Tribrid Mass Spectrometry. The identified peptides were screened for potential antibacterial activity using Random Forest and AdaBoost machine learning algorithms. The most promising peptide was chemically synthesized and evaluated in vitro for safety on rabbit red blood cells and activity against ESBL-producing E. coli (ATCC 35218) utilizing spot-on-lawn and broth dilution methods. Eight peptides ranging from 13 to 22 amino acids with molecular weights between 968.42 and 2434.11 Da were identified. Peptide NACAP-II was non-hemolytic to rabbit erythrocytes (p > 0.05) with a zone of inhibition (ZOI) of 22.7 ± 0.9 mm and a minimum inhibitory concentration (MIC) of 91.3 ± 1.2 μg/mL. The peptide is thus a candidate antibacterial compound with enormous potential applications in the pharmaceutical industry. However, further studies are still required to establish an upscale production strategy and optimize its activity and safety in vivo.

Funder

University of California, Davis

International Foundation for Science, Stockholm, Sweden

Publisher

MDPI AG

Reference56 articles.

1. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis;Murray;Lancet,2022

2. WHO (2023, April 18). WHO Priority Pathogens List for R&D of New Antibiotics. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.

3. Clinical Update Extended-Spectrum Beta-Lactamases: A Clinical Update;Paterson;Clin. Microbiol. Rev.,2005

4. Trends in Production of Extended-Spectrum β-Lactamases among Enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey;Luzzaro;J. Clin. Microbiol.,2006

5. Burden of Community-Onset Escherichia coli Bacteremia in Seniors;Jackson;J. Infect. Dis.,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3